Pancreatic Cancer Research

ResearcherUniversité Libre de BruxellesNo recent work listed

Raphaël Maréchal

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5027803580. Sources: OpenAlex.

Their work

Papers
21 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 3 papers · 2014: none · 2015: 5 papers · 2016: 5 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper

Papers 21

  1. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Co-author DOI 10.3390/cancers11111808↗
  2. Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. Co-author DOI 10.1016/j.ejrad.2018.04.024↗
  3. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Co-author DOI 10.1007/s00018-017-2579-9↗
  4. Vagal nerve activity predicts overall survival in metastatic pancreatic cancer, mediated by inflammation. First author DOI 10.1016/j.canep.2015.11.007↗
  5. Current standards and new innovative approaches for treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2015.12.026↗
  6. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer. Last author DOI 10.1038/bjc.2016.319↗
  7. Feasibility of Immunohistochemistry on Endoscopic Ultrasound Fine-Needle Aspiration Samples for Evaluating Predictive Biomarkers in Pancreatic Cancer Managemen… Co-author DOI 10.1097/mpa.0000000000000672↗
  8. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. Co-author DOI 10.18632/oncotarget.8527↗
  9. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000394↗
  10. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. Co-author DOI 10.1111/his.12577↗
  11. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0667↗
  12. Personalized medicine in pancreatic cancer: the revolution has begun. Co-author DOI 10.2217/pme.15.15↗
  13. [Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma]. Co-author PMID 26502580↗
  14. Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer. Co-author DOI 10.1007/s40266-013-0049-0↗
  15. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. First author DOI 10.1016/j.ejca.2013.04.017↗
  16. Towards a tailored therapy in pancreatic cancer. Co-author PMID 23650783↗
  17. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2012.06.006↗
  18. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  19. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. First author DOI 10.1093/annonc/mdr617↗
  20. Molecular changes in pancreatic cancer: implications for molecular targeting therapy. First author PMID 22870784↗
  21. Treatment of pancreatic cancer: what can we really predict today? First author DOI 10.3390/cancers3010675↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Luc Van Laethem · 16 shared papers, 2011–2018 · strength 0.80
  2. Jean‐Baptiste Bachet · 15 shared papers, 2011–2019 · strength 0.67
  3. Pieter Demetter · 10 shared papers, 2012–2016 · strength 0.38
  4. Jerome F. Cros · 7 shared papers, 2013–2019 · strength 0.35
  5. Francesco Puleo · 6 shared papers, 2015–2019 · strength 0.34
  6. Magali Svrcek · 8 shared papers, 2012–2019 · strength 0.34
  7. Pascal R. Hammel · 6 shared papers, 2012–2015 · strength 0.17
  8. Thierry André · 5 shared papers, 2012–2015 · strength 0.15
  9. Christophe Louvet · 5 shared papers, 2012–2015 · strength 0.13
  10. Anne Couvelard Benveniste · 3 shared papers, 2012–2019 · strength 0.12
  11. François Paye · 4 shared papers, 2012–2015 · strength 0.11
  12. Alain Sauvanet Sauvanet · 4 shared papers, 2012–2015 · strength 0.11
  13. Celso Matos · 1 shared paper, 2018 · strength 0.08
  14. Maria Antonietta Bali · 1 shared paper, 2018 · strength 0.08
  15. Thierry Conroy · 2 shared papers, 2012–2016 · strength 0.08
  16. Michel Pierre Ducreux · 2 shared papers, 2012–2016 · strength 0.08
  17. Juan Iovanna · 2 shared papers, 2012–2017 · strength 0.08
  18. Jacques M.E. Deviere · 2 shared papers, 2012–2016 · strength 0.08
  19. Marijke Couck · 1 shared paper, 2016 · strength 0.08
  20. Yori Gidron · 1 shared paper, 2016 · strength 0.08
  21. Rémy Nicolle · 1 shared paper, 2019 · strength 0.08
  22. Pierre Laurent‐Puig · 1 shared paper, 2019 · strength 0.08
  23. Jérôme Raffenne · 1 shared paper, 2019 · strength 0.08
  24. Valérie Paradis · 1 shared paper, 2019 · strength 0.08
  25. Louis de Mestier · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.